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1875-9572/Copyright ª 2013, Taiwan
CC BY-NC-ND license (http://creativePemphigus vulgaris (PV) is an autoimmune disease in which the autoantibody, immunoglobulin
G, is directed against the keratinocytes in the epidermis. The classic presentations of PV are
flaccid vesicles or bullae over the oral mucosa, trunk, groin, and extremities. The age of onset
is usually between 40 and 60 years, and cases of PV in children or adolescent patients are rare.
Here, we present a 17-year-old boy who had painful oral ulcers for 3 months initially and bullae
spreading to the whole body in the following days. Paraneoplastic pemphigus was another dif-
ferential diagnosis due to the atypical appearance of the skin lesion. However, PV was
confirmed by hematoxylin and eosin staining and immunofluorescence examination of the skin
biopsy specimens. The patient had a good response to corticosteroid treatment and the immu-
nosuppressive agent, rituximab.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Pemphigus vulgaris (PV) is an autoimmune blistering disease
of the skin and mucous membranes. Autoantibodies
directed against the surface of keratinocytes leads to thechang Rd., Shilin Dist., Taipei
211x2695.
m.tw (L.-J. Wang).
013.08.008
Pediatric Association. Published
commons.org/licenses/by-nc-ndloss of cell-to-cell adhesion in the epidermis. The age of
onset is usually between 40 and 60 years. The disease rarely
affects children and adolescent patients.1e4 PV is treated
with high doses of systemic corticosteroids to control the
painful and spreading lesions during the acute phase. Once
the acute phase is controlled, immunosuppressive agents
(ISAs) are used for the steroid-sparing effect and to reduce
the production of pathogenic autoantibody. We herein
report the case of a 17-year-old adolescent who hadby Elsevier Taiwan LLC. This is an open access article under the
/4.0/).
Oral ulcers as an initial presentation 339chronic oral ulcers initially and was diagnosed with PV
based on the histopathologic and direct immunofluores-
cence (DIF) findings.2. Case report
A 17-year-old, previously healthy, Taiwanese boy presented
with a 3-month history of painful oral ulcers. Initially, he
had been diagnosed with handefootemouth disease. He
received some supportive treatments such as analgesic
drugs and local anesthetic spray but the effect was limited
and the oral ulcers persisted. He denied any recent medi-
cation use or infections. There was no family history of
autoimmune disease.
He had regular follow-up at the outpatient department
of ears, nose, and throat. The oral ulcers persisted and
refractory mucositis was impressed; therefore, predniso-
lone (0.35 mg/kg/day) was prescribed 1 month before this
admission. However, its effect was limited. Furthermore,
multiple vesicles arose from the lip, neck, hands, trunk,
extremities, and groin to the buttocks. Because of these
problems, he was referred to our outpatient clinic.
He had cough for 6e8 weeks, fatigue, and weight loss
(4 kg), which were attributed to painful oral ulcers. He was
underweight (body mass index: 16 kg/m2) with pallid
appearance. Facial examination revealed multiple oral ul-
cers with crust and necrotic tissue distributed from the
outer lip to the soft and hard palate (Figure 1).Figure 1 Oral ulcers with necrotic tissue on the top.Furthermore, round vesicles and bullae with serous
content, slightly tensed, were scattered across the trunk
and four limbs (Figure 2). The initial differential diagnosis
included herpes virus infection, human immunodeficiency
virus (HIV) infection, Behc¸et’s disease, and immune defi-
ciency (Table 1). The Tzanck smear test was performed,
which revealed a multinucleated giant cell.
Laboratory investigations revealed eosinophilia (9.2%)
and lymphocyte-predominant white blood cell differentia-
tion (50.4%), elevated erythrocyte sedimentation rate
(18 mm/hour), elevated C-reactive protein (1.08 mg/dL),
decreased immunoglobulin G (IgG) level (623 mg/dL), and
negative titers for HIV screen, antinuclear antibodies,
blood culture, herpes simplex virus-1 (HSV-1) IgM, HSV-2
IgM, and VZV IgM, but positive titer for varicella-zoster virus
IgG. A chest X-ray showed increasing bilateral lung
infiltration.
He received acyclovir (1500 mg/m2/day) for the initial
impression (chicken pox infection). Oxacillin (93 mg/kg/
day) was also infused to cover the secondary bacterial
infection. Intravenous Ig (IVIG; 976 mg/kg/day) was injec-
ted for 2 days for the low IgG level, which we considered
might be related to the poor nutritional status over the
past 3 months. However, the result was not so satisfactory.Figure 2 Vesicles and bullae spread to the trunk.
Table 1 Summary of the differential diagnosis of oral ulcers.
Disease Clinical presentation Treatment Side effect
Laboratory data
Infection
HIV Generalized lymphadenopathy,
weight loss, opportunistic infection
Highly active
antiretroviral
therapy
Vary by drugs,
opportunistic
infectionHIV screen, Western blot
Herpes simplex virus Vesicular lesions on the tongue,
buccal mucosa, and vermilion border
Acyclovir Nausea, vomiting
Tzanck smear, culture, PCR
Varicella-zoster virus Papules, vesicles, pustules,
crusts simultaneously
Acyclovir Nausea, vomiting
Tzanck smear, culture, PCR
Handefootemouth
disease
Vesicles at the soft palate or
tonsil pillars
Symptomatic
treatment
d
Virus culture, PCR
Oral candidiasis White to creamy plaque Nystatin Abdominal pain,
nausea, vomitingFungus culture
Malignancy
Squamous cell
carcinoma
Sharply demarcarated,
hyperkeratotic macules or plaque
Topical
chemotherapy,
cryotherapy,
surgical excision
d
Biopsy
Melanoma Brown macules with irregular border Surgical excision d
Biopsy
Autoimmune disease
Systemic lupus e
rythematosus
Butterfly rash, scaly plaque Prednisolone,
immunosuppressive
drugs
Infection, renal or
hepatotoxicityPathology, ANAs, dsDNA
Behc¸et’s disease Recurrent aphthous ulcers, genital
ulcers, eye (uveitis) or skin lesion
(erythema nodosum)
Glucocorticoid,
colchicines,
azathioprine
Cushing syndrome,
osteoporosis
No pathognomonic laboratory tests
Reiter’s disease Arthritis, enthesitis, dysuria, urethritis,
oral ulcers
NSAID,
glucocorticoid
Dyspepsia, renal
toxicity
HLA-B27, rheumatoid factor
Cutaneous disease
Pemphigus Flaccid blister, mucosa involvement Prednisolone,
immunosuppressant,
methotrexate
Cushing syndrome,
osteoporosis,
opportunistic
infection
Pathology, DIF
Pemphigoid Tense bullae, pruritus Prednisolone,
immunosuppressant
Cushing syndrome,
osteoporosis,
opportunistic
infection
Pathology, DIF
Erythema multiforme Target lesions, involvement of mucus
membranes (oral ulcers, erythema)
Symptomatic
treatment
d
No specific laboratory tests indicated
Lichen planus Pruritus, purple, polygonal, planar,
papules, plaques
Topical steroid,
antihistamine, topical
retinoid
d
Clinical diagnosis, pathology
Aphthous stomatitis One or multiple round-to-ovoid, shallow,
painful oral ulcers
Corticosteroids,
chlorhexidine
gluconate
d
CBC, chemistry panel, nutritional workup
ANAs Z antinuclear antibodies; CBC Z complete blood count; DIF Z direct immunofluorescence; dsDNA Z double-stranded DNA;
HIV Z human immunodeficiency virus; HLA-B27 Z human leukocyte antigen B27; NSAID Z nonsteroidal anti-inflammatory drug;
PCR Z polymerase chain reaction.
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disease but the finding was negative. However, more flaccid
bullae emerged over the bilateral medial side of the thigh
during the hospitalization. Hence, skin biopsy was per-
formed. Histopathologic findings included acantholysis and
suprabasal keratinocyte. The DIF assessment showed
intercellular IgG and C3 staining mostly in the suprabasal
layer of the epidermis (Figure 3). Thus, pemphigus group
was diagnosed. Because of the younger age of presentation
and tense bullae on the neck and ankle, abdomen
computed tomography was performed to rule out para-
neoplastic pemphigus (PNP). The results indicated no
enlarged lymph nodes at the mediastinum, para-aortic re-
gion, or bilateral iliac chains. Therefore, we discontinued
acyclovir and instead prescribed intravenous methylpred-
nisolone (1.2 mg/kg/day).
After the steroid therapy, the patient’s condition
improved dramatically. The oral ulcers and vesicles healed
and his appetite improved. He was referred to a PV
specialist at the National Taiwan University Hospital (NTUH)
for further treatment. Even with high-dose prednisolone
usage, some vesicles persisted. Thus, after obtaining
informed consent, we prescribed intravenous rituximab
(500 mg) weekly for four doses as a unique protocol before
using other medications in treating PV at the dermatolog-
ical department of NTUH. Now, the disease is under control
without oral medications.3. Discussion
Pemphigus is a group of autoimmune blistering skin diseases
characterized by blister formation that occurs within the
epidermis caused by acantholysis, that is, the loss of
cohesion between epidermal cells. PV often starts in the
oropharynx and then spreads to areas that involve the
trunk, head, and intertriginous regions. Pemphigus is rarely
seen in childhood, with a mean age of 12 years at
presentation.5
Stomatitis is the presenting symptom in more than 50%
of cases. Epistaxis and hoarseness are also seen owing toFigure 3 Direct immunofluorescence showed immunoglob-
ulin G deposited in the intercellular substance of the
epidermis.involvement of the nose, pharynx, and larynx.5 Most pa-
tients present with painful oral erosions, and for some, this
is the only clinical manifestation.6 Months elapse before
skin lesions occur. These presentations fit the pattern of
this case. The diagnosis of PV is often delayed when oral
lesions are the only manifestation, and the index of suspi-
cion may be even lower in a young patient because of the
infrequent incidence of PV in children.5,7
The skin lesions on this patient were different from the
typical flaccid bullae developing in PV. The vesicles and
bullae were relatively tense. Therefore, PNP was suspected
due to its mimicking PV.8 In PNP, tense blisters with sur-
rounding erythema are more frequently seen on extremities
than on other areas.9 PNP has been associated with non-
Hodgkin lymphomas, thymomas, Castleman’s disease, and
chronic lymphocytic lymphoma. This young boy had neither
vacuolar interface dermatitis in the histopathologic exam-
ination nor IgG and complement deposition along the
basement membrane zone (BMZ) in the DIF finding. Thus,
PV was presumed.
Systemic corticosteroids, alone or in conjunction with
other ISA, are the mainstay of treatment for PV in child-
hood. These medications reduce the synthesis of anti-
bodies. Prednisolone is the first-line agent in doses of
1e2 mg/kg/day. In our case, methylprednisolone (1.2 mg/
kg/day) was used and the effect was promising. The ulcers
and bullae started to heal. IVIG (1 g/kg/day  2 days) was
given before the administration of steroid. However, the
skin lesion did not regress and newly formed bullae devel-
oped instead. The dose of IVIG used for PV was 2 g/kg/cycle
in the previous study.10 The frequency of the infusion was
monthly until satisfactory clinical response was achieved.
The total number of cycles varied from 19 to 61 months
(mean: 28.5 months).10 The indication for IVIG was lack of
response to prednisolone or the presence of side effects.
We suspect that one cycle of IVIG may not be enough to
achieve the clinical improvement. By contrast, the high
cost of IVIG and possibility of cardiovascular events due to
hyperviscosity syndrome make IVIG a choice for patients
who have corticosteroid-refractory PV.11 Based on the
rationale that pemphigus is primarily an autoantibody-
driven autoimmune disorder, therapies that deplete
autoreactive B-cell clones have been investigated for the
treatment of pemphigus. Rituximab, a monoclonal antibody
directed against the CD20 antigen on B lymphocytes, has
demonstrated efficacy for PV and pemphigus foliaceus.
We report a case of juvenile PV that presented with
severe oral ulcers and generalized vesicles. The diagnosis
was delayed due to the infrequency and inexperience of
the disease in children. Learning from this case, autoim-
mune bullae disease must be included in the differential
diagnosis when a child has severe or refractory oral lesions.
PNP must be ruled out if there are atypical vesicles and the
possibility of undiscovered malignancy. Steroid is the first-
line medication of PV and rituximab is promising in re-
fractory cases or steroid-sparing effect.References
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